These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35373859)

  • 21. Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels.
    Knab VM; Corbin B; Andrukhova O; Hum JM; Ni P; Rabadi S; Maeda A; White KE; Erben RG; Jüppner H; Christov M
    Endocrinology; 2017 May; 158(5):1130-1139. PubMed ID: 28324013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of Fibroblast Growth Factor 23 in Human Plasma.
    Cui S; Vaingankar SM; Stenger A; Waikar SS; Leaf DE
    J Appl Lab Med; 2017 May; 1(6):729-734. PubMed ID: 33379820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction.
    Ghuman J; Cai X; Patel RB; Khan SS; Hecktman J; Redfield MM; Lewis G; Shah SJ; Wolf M; Isakova T; Mehta R
    J Card Fail; 2021 Mar; 27(3):309-317. PubMed ID: 33035687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.
    Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2016 Mar; 46(3):234-41. PubMed ID: 26728476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
    Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
    Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos.
    Mehta R; Cai X; Hodakowski A; Thyagarajan B; Zeng D; Zee PC; Wohlgemuth WK; Redline S; Lash JP; Wolf M; Isakova T
    Bone; 2018 Sep; 114():278-284. PubMed ID: 29986841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
    Iwasaki T; Fujimori A; Nakanishi T; Okada S; Hanawa N; Hasuike Y; Kuragano T
    BMC Nephrol; 2021 Apr; 22(1):124. PubMed ID: 33832448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-Analysis of the Association between Fibroblast Growth Factor 23 and Mortality and Cardiovascular Events in Hemodialysis Patients.
    Gao S; Xu J; Zhang S; Jin J
    Blood Purif; 2019; 47 Suppl 1(Suppl 1):24-30. PubMed ID: 30699419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia.
    van Vuren AJ; Eisenga MF; van Straaten S; Glenthøj A; Gaillard CAJM; Bakker SJL; de Borst MH; van Wijk R; van Beers EJ
    Blood Adv; 2020 Apr; 4(8):1678-1682. PubMed ID: 32324886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
    Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
    Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EPO-FGF23 Signaling Pathway in Erythroid Progenitor Cells: Opening a New Area of Research.
    van Vuren AJ; Gaillard CAJM; Eisenga MF; van Wijk R; van Beers EJ
    Front Physiol; 2019; 10():304. PubMed ID: 30971944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Intact Fibroblast Growth Factor 23 Levels Are Negatively Associated with Bone Mineral Density in Chronic Hemodialysis Patients.
    Lee WT; Fang YW; Chen M; Liou HH; Lee CJ; Tsai MH
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients.
    Egli-Spichtig D; Hamid AK; Arroyo EMP; Ketteler M; Wiecek A; Rosenkranz AR; Pasch A; Lorenz H; Hellmann B; Karus M; Ammer R; Rubio-Aliaga I; Wagner CA
    Clin Kidney J; 2023 Oct; 16(10):1622-1633. PubMed ID: 37779856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium.
    McKenna MJ; Crowley RK; Twomey PJ; Kilbane MT
    JBMR Plus; 2021 Feb; 5(2):e10437. PubMed ID: 33615106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
    Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
    J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial.
    Stöhr R; Brandenburg VM; Heine GH; Maeder MT; Leibundgut G; Schuh A; Jeker U; Pfisterer M; Sanders-van Wijk S; Brunner-la Rocca HP
    Eur J Heart Fail; 2020 Apr; 22(4):701-709. PubMed ID: 32020782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibroblast growth factor 23 and Klotho serum levels in healthy children.
    Gkentzi D; Efthymiadou A; Kritikou D; Chrysis D
    Bone; 2014 Sep; 66():8-14. PubMed ID: 24880094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of FGF23 processing in fibrous dysplasia.
    Bhattacharyya N; Wiench M; Dumitrescu C; Connolly BM; Bugge TH; Patel HV; Gafni RI; Cherman N; Cho M; Hager GL; Collins MT
    J Bone Miner Res; 2012 May; 27(5):1132-41. PubMed ID: 22247037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral iron supplementation with sodium ferrous citrate reduces the serum intact and c-terminal fibroblast growth factor 23 levels of maintenance haemodialysis patients.
    Yamashita K; Mizuiri S; Nishizawa Y; Kenichiro S; Doi S; Masaki T
    Nephrology (Carlton); 2017 Dec; 22(12):947-953. PubMed ID: 27558654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?
    Bożentowicz-Wikarek M; Kocełak P; Owczarek A; Olszanecka-Glinianowicz M; Mossakowska M; Skalska A; Więcek A; Chudek J
    Clin Biochem; 2015 Apr; 48(6):431-6. PubMed ID: 25583093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.